Kura Oncology (NASDAQ:KURA) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Kura Oncology (NASDAQ:KURA – Free Report) in a research note issued to investors on Friday morning, Benzinga reports. Cantor Fitzgerald currently has a $30.00 price target on the stock. A number of other equities analysts also recently issued reports on KURA. BTIG Research initiated coverage on […]

Related Keywords

United States ,Stifel Nicolaus ,Thomas Malley ,Kura Oncology Inc ,Allspring Global Investments Holdings ,Cantor Fitzgerald ,Nisa Investment Advisors ,Securities Exchange Commission ,Denali Advisors ,Kura Oncology ,Free Report ,Moderate Buy ,Oncology Stock Down ,Get Free Report ,Director Thomas Malley ,Exchange Commission ,Investment Advisors ,Global Investments Holdings ,Gyon Technologies Capital Management ,Lysinek Specific Methyltransferase ,Kura Oncology Daily ,Nasdaq Kura ,Kura ,Medical ,Reiterated Rating ,